Standard BioTools to report Q2 2025 financial results on August 11.
PorAinvest
lunes, 21 de julio de 2025, 7:06 am ET1 min de lectura
LAB--
Investors can participate in the conference call by dialing:
- US domestic callers: (888) 346-3970
- Outside US callers: (412) 902-4297
The live audio of the webcast will be available online on the Investor Relations page of the company's website. The webcast will also be archived and accessible on the Investor Relations page at investors.standardbio.com.
Standard BioTools Inc., a leading provider of next-generation technologies, focuses on helping biomedical researchers develop better medicines faster. The company's proprietary technologies, including SomaScan, mass cytometry, and microfluidics, enable reliable and repeatable insights in health and disease, transforming scientific discoveries into improved patient outcomes.
For more information, visit Standard BioTools' Investor Relations page at investors.standardbio.com or connect with them on social media platforms like X, Facebook®, LinkedIn, and YouTube™.
References:
[1] https://www.stocktitan.net/news/LAB/standard-bio-tools-schedules-second-quarter-earnings-conference-call-mr4qp52zdn2w.html
• Standard BioTools reports Q2 2025 financial results on Aug 11, 2025. • Company will host conference call and webcast at 4:30 p.m. ET. • Dial-in for US domestic callers: 888-346-3970. • Dial-in for outside US callers: 412-902-4297. • Live audio available on company's website. • Webcast will be archived on the Investor Relations page.
Standard BioTools Inc. (NASDAQ: LAB) has scheduled its second quarter 2025 earnings conference call for Monday, August 11, 2025, following the market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss its financial results and operational progress for the quarter.Investors can participate in the conference call by dialing:
- US domestic callers: (888) 346-3970
- Outside US callers: (412) 902-4297
The live audio of the webcast will be available online on the Investor Relations page of the company's website. The webcast will also be archived and accessible on the Investor Relations page at investors.standardbio.com.
Standard BioTools Inc., a leading provider of next-generation technologies, focuses on helping biomedical researchers develop better medicines faster. The company's proprietary technologies, including SomaScan, mass cytometry, and microfluidics, enable reliable and repeatable insights in health and disease, transforming scientific discoveries into improved patient outcomes.
For more information, visit Standard BioTools' Investor Relations page at investors.standardbio.com or connect with them on social media platforms like X, Facebook®, LinkedIn, and YouTube™.
References:
[1] https://www.stocktitan.net/news/LAB/standard-bio-tools-schedules-second-quarter-earnings-conference-call-mr4qp52zdn2w.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios